100 million pounds is the price to pay for being the owner of the apartment the world’s most expensive. For that price, an exceptional view of the park, an ultra-sophisticated air purification, walls and windows and a shielded panic room…

NicOx SA (Euronext Paris: COX) today announced the lifting of a total of about 100 million euros via a capital increase in two stages. The second step was the realization of a capital increase with retention of preferential subscription rights, launched November 25, 2009, which helped raise total gross proceeds of 69.9 million euros and led to the Issue of 20,042,031 new shares.

These funds will support the strategic goal of becoming one of NicOx specialist pharmaceutical company, with sales operations targeting specialists in the United States, allowing him to play a direct role in the marketing of naproxcinod, and create value for shareholders with its portfolio of innovative research and development.

Eric Castaldi, Chief Financial Officer at NicOx, said: We are very pleased with the success of this capital increase, successful with the support of our shareholders and new investors. The 100 million euros raised at the end of this funding in two stages allow NicOx to pursue its strategic goal of establishing a direct commercial presence in the United States.

Total demand for new shares in the capital increase with retention of preferential subscription amounted to approximately 104 million euros, corresponding to an oversubscription of 149%. The exercise of preferential rights of subscription as covered 18,578,755 new shares, representing 92.7% of new shares to be issued. The subscription for excess focused on 11,323,873 shares and will therefore only partially allocated, with the issuance of 1,463,276 new shares.



.